The results showed that LINC00839 overexpression promoted tumor growth and radiation resistance; while celecoxib treatment efficiently suppressed tumor growth, whereas celecoxib and irradiation combinational treatment exhibited the strongest tumor inhibition (Fig. 7E). The gene discussed is LINC00839; the disease is neoplasm.